Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ACET | US
-0.07
-4.70%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
04/10/2024
1.42
1.42
1.45
1.40
Adicet Bio Inc. a clinical stage biotechnology company discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting facilitate innate and adaptive anti-tumor immune response and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001 which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002 which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925 a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio Inc. is based in Boston Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
61.2%1 month
55.8%3 months
66.3%6 months
78.0%-
-
0.50
0.08
0.07
-1.21
2.14
0.82
-121.50M
117.01M
117.01M
-
-
-
-100.00
-57.91
9.17
6.01
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.21
Range1M
0.31
Range3M
0.63
Rel. volume
0.21
Price X volume
173.75K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Veru Inc | VERU | Drug Manufacturers-Specialty & Generic | 0.7699 | 112.70M | 2.15% | n/a | 36.36% |
Karyopharm Therapeutics Inc | KPTI | Drug Manufacturers-Specialty & Generic | 0.8874 | 110.64M | 0.40% | n/a | -148.05% |
Assertio Therapeutics Inc | ASRT | Drug Manufacturers-Specialty & Generic | 1.14 | 108.68M | 1.79% | n/a | 30.76% |
OptiNose Inc | OPTN | Drug Manufacturers-Specialty & Generic | 0.7107 | 107.16M | 5.95% | n/a | -294.40% |
Relmada Therapeutics Inc | RLMD | Drug Manufacturers-Specialty & Generic | 3.48 | 105.01M | 2.35% | n/a | 0.00% |
Benitec Biopharma Limited | BNTC | Drug Manufacturers-Specialty & Generic | 9.48 | 95.62M | -7.06% | n/a | 0.00% |
INC Research Holdings Inc | INCR | Drug Manufacturers-Specialty & Generic | 1.87 | 85.58M | 2.75% | n/a | 41.98% |
SCYNEXIS Inc | SCYX | Drug Manufacturers-Specialty & Generic | 1.44 | 54.51M | 0.70% | n/a | 25.73% |
Provectus Biopharmaceuticals Inc | PVCT | Drug Manufacturers-Specialty & Generic | 0.1014 | 42.58M | 4.54% | n/a | 0.00% |
DURECT Corporation | DRRX | Drug Manufacturers-Specialty & Generic | 1.24 | 38.49M | -7.46% | n/a | 318.92% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Unifi Inc | UFI | Textile Manufacturing | 6.74 | 123.04M | -2.46% | n/a | 52.56% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Culp Inc | CULP | Textile Manufacturing | 5.95 | 74.32M | -2.30% | n/a | 11.29% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6199 | 5.90M | 6.82% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.33 | 5.20M | 0.03% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.3899 | 3.55M | -0.01% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.4859 | 2.44M | -9.19% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.21 | 17.21 | Cheaper |
Ent. to Revenue | 2.14 | 334.38 | Cheaper |
PE Ratio | - | 26.92 | - |
Price to Book | 0.50 | 12.15 | Cheaper |
Dividend Yield | - | 2.77 | - |
Std. Deviation (3M) | 66.33 | 68.34 | Par |
Debt to Equity | 0.08 | -1.00 | Expensive |
Debt to Assets | 0.07 | 0.48 | Cheaper |
Market Cap | 117.01M | 5.31B | Emerging |